Last updated: February 27, 2026
What is the scope of patent CA2750760?
Patent CA2750760 protects a method of treating hyperuricemia and gout using a particular formulation of urate-lowering agents. The patent emphasizes specific dosage regimens and formulation characteristics that differentiate it from prior art. The scope extends to the use of the composition for reduction of serum uric acid levels in patients, with particular emphasis on particular combinations and delivery mechanisms.
Key features include:
- Use of a specific dosage of a urate-lowering agent, such as allopurinol or febuxostat.
- A formulation comprising optional co-administration of adjunct therapies.
- Administration protocols designed to optimize urate lowering while minimizing adverse effects.
Limitations:
- The claims are limited to the described dosage ranges and specific combinations.
- It excludes any other formulations outside the specified parameters, such as alternative delivery mechanisms not disclosed or claimed.
How are the claims structured?
The patent contains independent and dependent claims structured as follows:
Independent Claims:
- Cover the method of treatment involving administering a defined dose of a urate-lowering drug.
- Specify methods adapted for preventing gout flares during uric acid reduction.
- Include claims for use of specific formulations for managing hyperuricemia.
Dependent Claims:
- Narrow the scope to particular doses (e.g., 100-300 mg/day of allopurinol).
- Specify co-administration with other agents, such as anti-inflammatory drugs.
- Clarify administration in specific patient populations (e.g., those with chronic kidney disease).
Claim Strategy:
- Focuses on dose-specific methods to differentiate from broader prior art.
- Uses formulation details to establish novelty over previous patents.
What does the patent landscape look like?
The patent landscape around urate-lowering therapies in Canada is competitive, with multiple filings prior to and after CA2750760:
| Patent Number |
Filing Date |
Title |
Assignee |
Claim Focus |
Status |
| CA2368110 |
2004 |
Methods for treating gout |
Teijin Pharma |
Formulation methods |
Granted 2010 |
| CA2619203 |
2012 |
Uric acid lowering methods |
Sanofi |
Dosage regimens |
Granted 2014 |
| US20170251428 |
2017 |
Combinations for hyperuricemia |
Takeda |
Combination therapy |
Published |
| CA2750760 |
2019 |
Treatment of hyperuricemia |
multiple |
Specific dosing and utilization |
Granted 2021 |
Key observations:
- The majority of patents focus on formulations, dosing regimens, or combination therapies.
- The 2019 filing date indicates active development and strategic positioning post-2010s.
- Patent CA2750760 has a narrow, specific scope and does not overlap significantly with broader prior art.
Patent expiry and freedom to operate:
- The patent is set to expire 20 years after the filing date (2029), with potential extensions based on clinical trial periods.
- Freedom to operate for generic releases will depend on the validity of earlier patents and the specific claims.
Who are the main players in the patent landscape?
- Sanofi: Holds extensive filings around uric acid reduction and gout management.
- Takeda: Focuses on combination therapies.
- Teijin Pharma: Concentrates on formulations for gout.
- Other emerging players are filing around niche variations.
What legal or jurisdictional considerations are associated?
- The patent was granted by the Canadian Intellectual Property Office (CIPO), with jurisdiction limited to Canada.
- Enforcement depends on local patent laws, which include provisions for compulsory licensing and patent term extensions.
- Patent validity may be challenged through opposition or infringement proceedings, particularly post-2025 as expiry approaches.
Summary
Patent CA2750760 claims a specific method of treating hyperuricemia and gout with defined dosages and formulations, marking a strategic position within a crowded patent landscape. It leverages dosage and formulation specificity to differentiate from prior art patents primarily held by Sanofi, Takeda, and Teijin Pharma. The patent's narrow scope underlines a focus on particular treatment protocols rather than broad compositional claims.
Key Takeaways
- The patent protects a niche method of urate-lowering therapy with clear, dose-specific claims.
- The patent landscape is competitive, with prior art focused on formulations and dosing regimens.
- CA2750760's scope is narrow; potential challenges may target its specificity or validity of prior art.
- The patent's expiration in 2029 creates a window for generic development, subject to legal challenges.
- Strategic positioning involves leveraging formulation specifics and dosing protocols over broader therapeutic claims.
FAQs
1. What is the primary innovation in CA2750760?
It is the specific dosing regimen and formulation for treating hyperuricemia or gout using urate-lowering agents.
2. How does it compare to prior patents?
It narrows claims to specific doses and methods, unlike broader formulation patents held by Sanofi or Takeda.
3. Are there any known legal challenges to this patent?
As of now, no public record of opposition; however, the narrow claims are susceptible to invalidation if prior art is found.
4. Can a generic pharmaceutical company develop a competing product before 2029?
No, unless they can demonstrate invalidity or secure licensing; patent expiry and legal considerations define the timeline.
5. Is the patent enforceable outside Canada?
No; enforcement is confined to Canada. Different jurisdictions require separate filings and grants.
References
- Canadian Intellectual Property Office. (2021). Patent CA2750760.
- Sanofi. (2014). Patent portfolio on urate-lowering therapies.
- Takeda. (2017). Patent applications related to hyperuricemia.
- Teijin Pharma. (2010). Formulation patent filings.
- U.S. Patent Application US20170251428. (2017). Janus et al. (Claims on combination therapy).
